The infusion of capital speeds development of a novel ELANE‑targeted cancer therapy with broad preclinical efficacy, enhancing Onchilles' prospects for clinical success and signaling strong investor confidence in the biotech sector.
Onchilles Pharma Raises $25M in Series A1 Funding Round
Comments
Want to join the conversation?
Loading comments...